New Delhi: The authorities will on Friday conduct the second dry run for the COVID-19 vaccination roll-out in Delhi that will span across several districts of the national capital, officials said.
The districts include South Delhi, South East Delhi and North West Delhi and New Delhi, they said.
The first dry run for COVID-19 vaccination roll-out was held in Delhi on January 2 for which three sites were chosen across the national capital.
Delhi Health Minister Satyendar Jain had reviewed the exercise at a dispensary in Daryaganj, and said COVID-19 vaccine will be provided to people in the national capital for free once it arrives, and asserted that the city government has made all preparations for the vaccination drive.
The previous three sites were GTB Hospital Shahdara, Urban Primary Health Centre, Daryaganj, and Venkateshwar Hospital, Dwarka.
Officials on Thursday said 10 vaccination centres have been chosen in South Delhi district for the dry run, and the sites include AIIMS, Safdarjung Hospital, Pt Madan Mohan Malaviya Hospital, Pushpwati Singhania Hospital and Research Institute.
In South-East district, 19 sites have been chosen across three sub-divisions.
These sites include Batra Hospital, Fortis Hospital, Escorts Hospital, National Heart Institute, Holy Family Hospital, Apollo Hospital and MCW Gautampuri.
In North-West District, the 12 sites chosen for the exercise include Max Hospital and Fortis Hospital, both at Shalimar Bagh; Saroj Hospital, Jaipur Golden Hospital, and BSA Hospital, officials said.
Four sites have chosen in the New Delhi district, including NorthernRailway central hospital and Fortishospital, Vasant Kunj.
The Union health minister chaired an online meeting with health ministers of all states and union territories regarding COVID-19 vaccination dry run to be conducted on January 8 in all districts of the country, according to the bulletin issued by the Delhi health department on Thursday.
India's drugs regulator has approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.